Corneal thickness recovers after CXL

Article

After a corneal collagen cross-linking (CXL) procedure a patient's cornea thins but then recovers towards original thickness.

After a corneal collagen cross-linking (CXL) procedure a patient's cornea thins but then recovers towards original thickness, according to a one-year follow-up study published in the Journals of Cataract and Refractive Surgery.

Dr Peter S. Hersh et al., Cornea and Laser Eye Institute, New Jersey, USA, studied 54 eyes with keratoconus and 28 eyes with ecstasia after LASIK. The outcome measures were corneal thickness at the apex, the thinnest point and the pupil centre. These were measured at baseline and 1, 3, 6 and 12 months post-CXL.

Mean preoperative thinnest pachymetry was 440.7 μm ± 52.9 SD. Apex and corneal thickness returned to baseline after 1 year. Corneal thickness recovered more rapidly in ecstasia patients than in keratoconus patients. Although the researchers found that the corneal thickness was reduced up to 3-months post-op, the baseline thickness was recovered at 3 to 6-months follow-up.

In conclusion, the baseline thickness of the cornea is recovered after CXL but the causes and possible effects of this change in thickness still need to be explained.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.